Newsroom | Galderma US

Media Contacts

USMedia@galderma.com

Zach Randles-Friedman, Head of U.S. Communications: +1 305 299 5700

Galderma Announces FDA Approval of Restylane® Refyne and Restylane® Defyne Dermal Fillers for Treatment of “Laugh Lines”

Galderma to Share Data from Phase 3 Studies of New Investigational Restylane® Refyne and Restylane® Defyne at American Society for Dermatologic Surgery Annual Meeting

Leadership change at Nestlé Skin Health

Fort Worth-Based Galderma “Stuffs the Bus” with 1,250 Backpacks Full of School Supplies for Northwest ISD Students

Chugai and Galderma Announce Global License Agreement for Nemolizumab (CIM331), Novel Biologic for Skin Diseases

Galderma Announces FDA Approval of Full Prescription-Strength Differin® Gel For Over-the-Counter Acne Use

Galderma’s Cetaphil® Launches Limited-edition Product Display Honoring Camp Wonder

Galderma Invites Teens to Take a “Two-Week Challenge” with Benzac to Get Control of Acne Breakouts and Help Prevent Them from Coming Back

Galderma Celebrates 20th Global Anniversary of Restylane®

Galderma Announces Positive Results From The “CoMMPlete” Regiman Study Including EPIDUO® Gel In The Management Of Acne In Adolescent Student Athletes

Galderma Laboratories Announces Availability of New Mirvaso® (brimonidine) Topical Gel, 0.33%* Pump Dispenser for the Treatment of the Persistent Facial Redness of Rosacea

Galderma, Global Leader in Skin Health, Expands its Fort Worth Footprint